Westport Fuel Systems Inc (WPRT) Q1 2025 Earnings Call Highlights: Strategic Shifts and ...
Cespira Revenue: $16.7 million, not included in top line due to equity accounting.
Net Loss: Improved to $2.5 million from $13.6 million in Q1 2024.
Gross Margin: Increased to $15.2 million or 21% of revenue, up from $11.7 million or 15% in Q1 2024.
Operating Expenditures: Reduced by $8 million year-over-year.
Adjusted EBITDA: Improved to nil from a loss of $6.6 million in Q1 2024.
Light-Duty Revenue: $64.2 million, up from $63.3 million in Q1 2024.
High Pressure Control & Systems Revenue: $1.4 million, down from $2.4 million in Q1 2024.
Heavy-Duty OEM Revenue: $5.4 million, decreased due to transition to Cespira.
Cash and Cash Equivalents: $32.6 million as of March 31, 2025, down from $37.6 million at December 31, 2024.
Net Cash Used in Operating Activities: $4.9 million for Q1 2025.
Warning! GuruFocus has detected 3 Warning Signs with WPRT.
Release Date: May 14, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Westport Fuel Systems Inc (NASDAQ:WPRT) reported a significant improvement in net loss, reducing it to $2.5 million from $13.6 million in Q1 2024.
Gross profit increased by $3.5 million, and operating expenditures decreased by $8 million, indicating improved operational efficiency.
The company is focusing on high-growth areas by divesting its Light-Duty business to concentrate on long-haul and heavy-duty transport solutions.
Cespira, the joint venture with Volvo, generated $16.7 million in revenue, showcasing strong performance and potential for future growth.
Westport Fuel Systems Inc (NASDAQ:WPRT) is strategically positioned as a leader in alternative fuels, with innovations like the CNG HPDI solution enhancing its market offerings.
Reported revenue for Q1 2025 was $71 million, a 9% decrease compared to the same period last year.
The transition of the Heavy-Duty OEM business into Cespira resulted in a shift of revenue, impacting reported figures.
High Pressure Control & Systems revenues decreased to $1.4 million from $2.4 million in Q1 2024, primarily due to a slowdown in the hydrogen industry.
Cash and cash equivalents decreased to $32.6 million from $37.6 million at the end of 2024, indicating a reduction in liquidity.
The hydrogen infrastructure development is slowing, which could delay the adoption of hydrogen-powered automotive and industrial applications.
Q: Just to clarify on the divestiture. Is this closing in 2Q or has it already been closed? A: Closing in Q2.
Q: And that is when the cash proceeds, et cetera, will show up in the Q2 financials? Or will we see those in the third quarter financials? A: We expect to close by the end of the quarter, so the cash should show up in our June 30 balance sheet.
Q: With respect to Cespira margins going forward, any color on what the path to higher margins looks like? Is it just more volume that will drive this? A: Getting Cespira profitable is a combination of things. Volume is key, along with reducing costs and managing the supply base better.
Q: Last quarter, you mentioned the CNG related opportunity in North America. Any progress on that front? A: The pendulum is swinging back to natural gases. The hydrogen solutions are further off than expected, and the new US administration is pushing for natural gas, which should create opportunities.
Q: Is China going to be a focus for you as well in the new emerging Westport? A: Yes, China is important, representing 50% of our high-pressure components business. We are seeing natural gas accelerate in China, and we are developing products for customers there.
Q: Regarding the development of a CNG HPDI solution, how long would it take for Volvo to bring it to North America if they decide to? A: Engine development is a long cycle, typically about four years, mainly due to the certification process. We are proactively working to shorten this cycle.
Q: On the High-Pressure Controls business, what growth opportunities do you see in that segment? A: We have a strong book of business in hydrogen components, and we are pivoting to include CNG components. The market is pulling for local supply, especially in China.
Q: On the Cespira business, where is the growth coming from, and what are the dynamics? A: Growth is primarily in Europe, with Volvo marketing heavily and exploring opportunities in India. The 25% growth was built into our business plan.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Eli Lilly Fires Up GLP-1 Race in India With Mounjaro Pen Launch
Eli Lilly (NYSE:LLY) has rolled out its best-selling diabetes drug Mounjaro in a new injector pen format in India, intensifying its battle with Novo Nordisk in the fast-growing GLP-1 market. The Mounjaro Kwikpen, approved in June for six dose strengths from 2.5 mg to 15 mg, starts at ?14,000 ($160) for the lowest dose and rises to ?27,500 for the highest. Novo Nordisk's (NYSE:NVO) Wegovy, launched just days earlier in a similar format, is priced nearly in line across comparable doses. Warning! GuruFocus has detected 4 Warning Signs with VG. Lilly first entered India's obesity and diabetes market in March with Mounjaro vials and has already seen rapid uptake sales jumped 60% in May from April, according to Pharmarack Technologies. With both companies now offering user-friendly injector pens, competition is set to heat up in a country with more than 100 million diabetics and a rising obesity burden. Analysts see India as a key growth market for GLP-1 drugs as lifestyle diseases climb and awareness of newer therapies expands. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
LLY: Eli Lilly Stock Tanks -- Insiders Rush In With Millions
Aug 13 - Eli Lilly (NYSE:LLY) insiders jumped in after a sharp selloff, signaling confidence even as the market punishes recent drug trial results. The company's shares fell roughly 14% on disappointing interim data from the Phase 3 ATTAIN-1 trial for oral GLP-1 candidate orforglipron the biggest one-day drop in more than two decades. Warning! GuruFocus has detected 3 Warning Signs with BOM:532482. Instead of sitting on the sidelines, CEO David Ricks bought about 1.6K shares at an average $644.77 ($1M), while Chief Scientific Officer Dan Skovronsky added 1K shares at $634 apiece. Board members Gabrielle Sulzberger and Erik Frywald together picked up 1.7K shares, boosting insider ownership by a few percentage points. A few executives trimmed positions, notably Ilya Yuffa sold 1.3K shares, but the headline move remains management buying into the weakness. Analysts differ: some call the dip a rare buying window for long-term investors, others warn upside looks limited until clearer trial data arrive. For now, Lilly's insiders put money where their mouths are, betting the selloff overreacts to interim noise and that the company's broader growth drivers can stabilize sentiment. Is LLY Stock a Buy? Based on the one year price targets offered by 26 analysts, the average target price for Eli Lilly and Co is $914.51 with a high estimate of $1190.00 and a low estimate of $675.00. The average target implies a upside of +43.02% from the current price of $639.43. Based on GuruFocus estimates, the estimated GF Value for Eli Lilly and Co in one year is $1232.89, suggesting a upside of +92.81% from the current price of $639.43. Gf value is Gurufocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. For deeper insights, visit the forecast page. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
10 hours ago
- Yahoo
Cathie Wood Pours Millions Into Archer Aviation and Pony AI Push
Aug 13 - Cathie Wood's ARK funds made headlines again on Tuesday with a trio of bold moves in aviation and autonomy. ARK bought roughly $3.15 million of Archer Aviation (NYSE:ACHR) stock and added about $13.37 million of Pony AI (NASDAQ:PONY), signaling renewed appetite for eVTOL and robotaxi plays. At the same time ARK sold 282,737 shares of Kratos Defense (NASDAQ:KTOS), a disposal that totaled about $18.49 million as Wood rebalances the portfolio. Warning! GuruFocus has detected 2 Warning Sign with ACHR. The trades show ARK doubling down on next-gen mobility while trimming some defense exposure after KTOS's recent rally. Other smaller purchases included stakes in Caris Life Sciences (NASDAQ:CAI), Illumina (NASDAQ:ILMN) and Exact Sciences (NASDAQ:EXAS), alongside buys in mega-caps such as Amazon (NASDAQ:AMZN) and Deere (DE). ARK's move could push investor interest back into high-growth, speculative mobility names, but it also underscores the fund's active, high-conviction approach to thematic investing. This article first appeared on GuruFocus.
